Exiqon A/S Exiqon to Ring NASDAQ Closing Bell in New York

• Press Release
• Source: Exiqon A/S
• On 4:32 am EDT, Monday August 31, 2009

VEDBAEK, Denmark, Aug. 31, 2009 (GLOBE NEWSWIRE) -- Exiqon A/S (Copenhagen:EXQ - News) today announced that the company has been invited to ring the Closing Bell at The NASDAQ Stock Market on September 8, at 4:00 p.m. EST, in Times Square, New York City.

During September 8-10, Exiqon will be entertaining a number of investor meetings in New York, prior to a presentation of the company on September 10 at the Thomas Weisel Healthcare Conference at 11.30 a.m. EST at the Four Seasons Hotel in Boston.

"It is very important for us to have been invited to present Exiqon at the Thomas Weisel investor conference. It proves to us that our company is being recognized as a key player in our industry and in the development of modern molecular diagnostic tests for personalized cancer treatment selection", says Lars Kongsbak, president and CEO of Exiqon A/S.

Exiqon will be available for investor meetings in New York on September 8-9 and in Boston on September 10. Interested parties may contact the company at ir@exiqon.com.

To view the company's annual and quarterly reports, and for other investor-related information, please visit www.exiqon.com/investor.

Additional information Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 40902101) Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

About Exiqon

Exiqon is a biotech company with activities in three business areas where the company's technologies provide a competitive advantage: Sale of diagnostic tests (Exiqon Diagnostics), sale of innovative research products for miRNA research (Exiqon Life Sciences), and in contract research together with pharmaceutical companies (Exiqon Pharma Services). Exiqon is dedicated to personalizing the treatment selection for cancer patients. The aim is to optimize the use of existing medicine and avoid unnecessary and non-effective treatment. By using molecular diagnostic tests that analyze the genetic profile of each patient's tumor, treatment selection can be optimized for individuals. Exiqon is uniquely positioned to develop such new diagnostic tests. Exiqon already markets diagnostic tests that based on fresh tumor tissue enable doctors to test whether their patients are resistant to one or more of the chemotherapies offered to treat these patients and help them select an efficacious treatment. Exiqon's new molecular diagnostic products are based on the LNA(tm) technology that enables testing on fixed tissue. Launch of the first molecular diagnostic product was announced in December 2008. A number of new products will follow in the years ahead. Using the LNA(tm) technology is what has allowed Exiqon to establish a position for itself as one of the market's leading providers of research products for gene expression analysis. These research products are used by university scientists and in the pharmaceutical industry around the world to make groundbreaking discoveries about the correlation between gene activity and the development various diseases. Exiqon is also collaborating with pharmaceutical companies in their effort to develop new medicines based on biomarkers (Personalized Medicine). Exiqon has more than 170 employees and is listed on the NASDAQ OMX in Copenhagen and categorized as a biotech company (Small Cap+). Exiqon is financed until expected breakeven in 2011.

Buzz up!